| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EMP3 |
| Uniprot No | P54852 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-163aa |
| 氨基酸序列 | MSLLLLVVSALHILILILLFVATLDKSWWTLPGKESLNLWYDCTWNNDTKTWACSNVSENGWLKAVQVLMVLSLILCCLSFILFMFQLYTMRRGGLFYATGLCQLCTSVAVFTGALIYAIHAEEILEKHPRGGSFGYCFALAWVAFPLALVSGIIYIHLRKRE |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EMP3重组蛋白的3篇参考文献概览：
1. **文献名称**: *EMP3 modulates glioblastoma cell proliferation and migration via regulation of NF-κB signaling*
**作者**: Wang L, et al.
**摘要**: 该研究利用重组EMP3蛋白处理胶质瘤细胞，发现其通过抑制NF-κB信号通路显著降低细胞增殖和迁移能力，提示EMP3在胶质母细胞瘤中具有抑癌作用。
2. **文献名称**: *Recombinant EMP3 protein induces apoptosis in hepatocellular carcinoma through ER stress activation*
**作者**: Chen X, et al.
**摘要**: 作者通过大肠杆菌系统表达重组EMP3蛋白，证实其能诱导肝癌细胞内质网应激，激活Caspase-3依赖性凋亡通路，为肝癌治疗提供潜在靶点。
3. **文献名称**: *Structural and functional characterization of EMP3 in lipid raft organization*
**作者**: Müller R, et al.
**摘要**: 本研究解析了重组EMP3蛋白的晶体结构，发现其C端结构域与细胞膜脂筏形成相关，并通过体外实验证明EMP3缺失会破坏脂筏完整性，影响细胞膜信号传递。
---
**注**：上述文献为示例性质，实际引用时需以具体检索结果为准。建议通过PubMed或Web of Science以关键词“EMP3 recombinant protein”或“EMP3 expression and function”查找最新研究。
**Background of EMP3 Recombinant Protein**
EMP3 (Epithelial Membrane Protein 3) is a member of the peripheral myelin protein 22 (PMP22) gene family, primarily localized to cell membranes. It plays roles in cell adhesion, differentiation, and signal transduction, with emerging links to myelination processes and tumorigenesis. Structurally, EMP3 contains four transmembrane domains and shares homology with other PMP22 family proteins involved in maintaining membrane integrity. Dysregulation of EMP3 has been implicated in cancers (e.g., gliomas, breast cancer) and neurological disorders, where it may act as a tumor suppressor or promoter depending on context.
Recombinant EMP3 refers to the engineered protein produced via heterologous expression systems (e.g., *E. coli*, mammalian cells). This method enables large-scale production of purified EMP3 for functional studies. Researchers utilize recombinant EMP3 to investigate its interactions with membrane proteins (e.g., integrins, growth factor receptors), its role in regulating apoptosis or metastasis, and its potential as a therapeutic target or biomarker.
In neuroscience, EMP3 is critical for myelination, and recombinant forms aid in studying demyelinating diseases like Charcot-Marie-Tooth. However, challenges persist in resolving EMP3’s 3D structure and post-translational modifications, which recombinant proteins help address. Commercial EMP3 recombinant proteins are often tagged (e.g., His-tag) for ease of purification and detection in assays such as Western blotting or ELISA.
Current research focuses on clarifying EMP3’s dual roles in cancer progression/regression and its utility in diagnostic or therapeutic strategies. The development of bioactive recombinant EMP3 remains pivotal for advancing these applications.
×
